The revenue beat and raised guidance confirm strong execution, but the stock's 6.5% normal daily move means the 23% revenue growth and 33% Data & Apps growth are already partly priced in. Watch the Personalis shareholder vote on Nov 30 and Q4 cash flow trends for margin inflection.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $78.48entry
- T+1 · 14d ago −0.87%α −1.17% · $77.80
- T+5 · 8d ago +7.59%α +7.52% · $84.44
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The company raised full-year 2026 revenue guidance to $1.60-$1.605B (from $1.595-$1.605B), representing ~25% annual growth, and reiterated ~$65M Adjusted EBITDA. Key operational highlights include 32% oncology volume growth, 33% Data & Apps revenue growth, and major collaborations with BMS ($137.5M) and Merck/Moderna. The Personalis acquisition cleared regulatory review with a shareholder vote scheduled for November 30, 2026.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue of $411.5M, up 23% YoY from $334.2M
- GAAP net loss of $(14.9)M vs $(80.0)M in Q3 2025, improvement of 81%
- Adjusted EBITDA of $25.6M vs $1.5M in Q3 2025, a 1,633% increase
- Full-year 2026 revenue guidance raised to $1.60-$1.605B from $1.595-$1.605B
- Data & Applications revenue grew 33% YoY to $108.1M
- Oncology volume growth accelerated to 32% YoY
- MRD volume of ~12,000 tests, up 300% YoY
- BMS collaboration: up to $137.5M over five years for oncology data and models
- Merck/Moderna multi-year collaboration for individualized neoantigen therapy (INT)
- Personalis acquisition cleared regulatory review; shareholder vote set for Nov 30, 2026
- Cash and marketable securities of $854.4M at quarter end
- Data licensing bookings >$550M year-to-date
Financial Impact
Revenue beat consensus by ~$2.2M (0.5%), guidance raised modestly, Adjusted EBITDA improved sharply to $25.6M from $1.5M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Diagnostics | $303.5M | +20.0% |
| Data and Applications | $108.1M | +33.0% |
Risk Factors
- Personalis acquisition integration risk and potential dilution
- Heavy stock-based compensation ($48.1M in Q3) continues to pressure GAAP profitability
- Revenue concentration in related-party transactions (Pathos AI, SB Tempus)
- High cash burn: operating cash flow of $(71.6)M YTD 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-442619 |
| Document: tem-20261102.htm | 0001193125-26-442619 |
| Document: 0001193125-26-442619-index-headers.html | 0001193125-26-442619 |
| Document: 0001193125-26-442619-index.html | 0001193125-26-442619 |
| Document: 0001193125-26-442619.txt | 0001193125-26-442619 |
| 8-K Data (Synthetic) | 0001193125-26-442619 |
Track record
45 reports on TEM
8 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +53.09% at T+60 after the Jul 30, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $80.54 Now $64.76 −19.59% settles Feb 8
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $76.05 Now $64.76 −14.85% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 3/10 Entry $70.43 Now $64.76 −8.05% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $77.80 Now $64.76 −16.76% settles Feb 1
- Nov 2, 202614d ago 8-K Bullish 6/10 Viewing Entry $78.48 Now $64.76 −17.48% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $77.84 Now $64.76 −16.80% settles Jan 27
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 27, 202620d ago 144 Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $67.62 Now $64.76 −4.22% settles Jan 21
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $63.81 Now $64.76 +1.49% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers